留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

治疗心房纤颤和扑动的新药决奈达隆

吕娟丽 刘洋 李彦 刘振华

吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
引用本文: 吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
Citation: LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.

治疗心房纤颤和扑动的新药决奈达隆

Dronedarone a new drug for atrial fibrillation or atrial flutter

  • 摘要: 决奈达隆为胺碘酮的类似物,结构中不含碘,减少了碘所致的器官毒性,为新型的抗心律失常药。2009年7月1日获FDA批准,用于治疗心房纤颤或心房扑动的心脏病患者。本文通过对决奈达隆进行文献检索,对其药理作用、药动学、临床评价、药物相互作用、不良反应等方面进行了综述。
  • [1] Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States.1980~1998[J]. Am J Epidemiol,2002,155(9):819.
    [2] Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization foratrial fibrillation in the United States, 1985 through 1999: implications for primary prevention[J]. Circulation ,2003,108(6):711.
    [3] Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial[J]. Lancet,2000, 356(9244):1789.
    [4] Wyse DG, Waldo AL, DiMarco JP,et al.Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002,347(23):1825 .
    [5] Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects[J]. J Cardiovasc Electrophysiol.2006, 17(12):S17.
    [6] Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone[J]. Circulation, 1999,100(22):2276 .
    [7] Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs[J]. Eur J Pharmacol,1995,279(1):25.
    [8] Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart[J].Eur J Pharmacol ,2004,496(1-3):119.
    [9] Celestino D, Medei E, Moro S,et al. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study[J]. J. Cardiovasc Pharmacol Ther,2007, 12(3): 248.
    [10] Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone[J]. J Cardiovasc Pharmacol, 2002,39(5):677.
    [11] Varró A, Takács J, Németh M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone[J]. Br J Pharmacol,2001,133(5):625.
    [12] Chatelain P, Meysmans L, Mateazzi Jr, et al. Clinietm: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β-adrenoceptor and adenylate cyclase in rat heart[J]. Br J Pharmacol,1995 ,116(3):1949.
    [13] Pantos C, Mourouzis I, Delbruyere M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and post ischemic performance of the isolated rat heart[J]. Eur J Pharmacol, 2002, 444(3):191.
    [14] Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study[J]. Eur Heart J ,2003, 24 (16): 1481
    [15] Singh BN, Connolly SJ, Crijns HJ,et al.EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med, 2007,357(10): 987.
    [16] Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study[J]. Am. Heart J,2008,156(3):527.
    [17] KΦber L , TorpPedersen C , McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure[J]. N Engl J Med ,2008 ,358 (25) :2678.
    [18] Hohnloser SH, Crijns HJ, van Eickels M,et al.ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med ,2009,360(7): 668.
    [19] Sanofi-Aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [EB/OL]. (2008-12-23) http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf.
    [20] Dale KM, White CM.Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter[J]. Ann Pharmacother,2007,41(4):599.
    [21] Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials[J]. Am J Cardiol ,2003, 91(6A):15D.
    [22] Patel PD, Bhuriya R, Patel DD,et al. Dronedarone for atrial fibrillation: a new therapeutic agent[J]. Vasc Health Risk Manag,2009,5:635.
    [23] Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol, 2004,287(2):L438.
    [24] Van Beeren HC, Jong WM, Kaptein E,et al. Dronedarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence[J]. Endocrinology ,2003,144(2):552.
    [25] Zipes DP, Camm AJ, Borggrefe M,et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines[J]. Circulation. 2006 ,114(10):e385.
    [26] Tschuppert Y,Buclin T,Rothuizen LE,et al. Effect of dronedarone on renal function in healthy subjects[J].Br J Clin Pharmacol,2007,64(6): 785.
  • [1] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
    [2] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [3] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
  • 加载中
计量
  • 文章访问数:  2316
  • HTML全文浏览量:  256
  • PDF下载量:  110
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-03-04
  • 修回日期:  2010-03-11

治疗心房纤颤和扑动的新药决奈达隆

摘要: 决奈达隆为胺碘酮的类似物,结构中不含碘,减少了碘所致的器官毒性,为新型的抗心律失常药。2009年7月1日获FDA批准,用于治疗心房纤颤或心房扑动的心脏病患者。本文通过对决奈达隆进行文献检索,对其药理作用、药动学、临床评价、药物相互作用、不良反应等方面进行了综述。

English Abstract

吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
引用本文: 吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
Citation: LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
参考文献 (26)

目录

    /

    返回文章
    返回